Guidelines for biological treatment of substance use and related disorders,part 1: Alcoholism,first revision |
| |
| Authors: | Michael Soyka Henry R. Kranzler Victor Hesselbrock Siegfried Kasper Jochen Mutschler Hans-Jürgen Möller |
| |
| Affiliation: | 1. Psychiatric Hospital Meiringen, Meiringen, Switzerland;2. Department of Psychiatry, Ludwig-Maximilians-University, Munich, Germany;3. Medicalpark Chiemseeblick, Bernau, Germany;4. Crescenz VAMC, University of Pennsylvania and VISN 4 MIRECC, Philadelphia, PA, USA;5. University of Connecticut Health, Farmington, CT, USA;6. Department of Psychiatric Medicine, University of Vienna, Vienna, Austria;7. Psychiatric Hospital University of Zürich, Zürich, Switzerland;8. Department of Psychiatry, Ludwig-Maximilians-University, Munich, Germany |
| |
| Abstract: | These practice guidelines for the biological treatment of alcohol use disorders are an update of the first edition, published in 2008, which was developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). For this 2016 revision, we performed a systematic review (MEDLINE/PUBMED database, Cochrane Library) of all available publications pertaining to the biological treatment of alcoholism and extracted data from national guidelines. The Task Force evaluated the identified literature with respect to the strength of evidence for the efficacy of each medication and subsequently categorised it into six levels of evidence (A–F) and five levels of recommendation (1–5). Thus, the current guidelines provide a clinically and scientifically relevant, evidence-based update of our earlier recommendations. These guidelines are intended for use by clinicians and practitioners who evaluate and treat people with alcohol use disorders and are primarily concerned with the biological treatment of adults with such disorders. |
| |
| Keywords: | Alcoholism pharmacotherapy acamprosate baclofen naltrexone nalmefene topiramate carbamazepine disulfiram ondansetron benzodiazepine |
|
|
